相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death
Simeng Wen et al.
CANCER TREATMENT REVIEWS (2014)
Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Chengfei Liu et al.
CLINICAL CANCER RESEARCH (2014)
A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells
Karishma S. Amin et al.
MOLECULAR CANCER THERAPEUTICS (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
New Therapeutic Approach to Suppress Castration-Resistant Prostate Cancer Using ASC-J9 via Targeting Androgen Receptor in Selective Prostate Cells
Kuo-Pao Lai et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
Yingming Li et al.
CANCER RESEARCH (2013)
An androgen receptor N-terminal domain antagonist for treating prostate cancer
Jae-Kyung Myung et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Defining a new testosterone threshold for medical castration: Results from a prospective cohort series
Shawn Dason et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2013)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
Galectin-1 suppression enhances combined anti-EGFR and radiation-therapy of NSCLC
Michael Siedow et al.
CANCER RESEARCH (2012)
A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERα protein
Chi Tze Tiong et al.
CARCINOGENESIS (2012)
A transcriptional repressor co-regulatory network governing androgen response in prostate cancers
Kern Rei Chng et al.
EMBO JOURNAL (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Alternatively spliced androgen receptor variants
Scott M. Dehm et al.
ENDOCRINE-RELATED CANCER (2011)
Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Raymond J. Andersen et al.
CANCER CELL (2010)
Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2009)
Pharmacokinetics of prenylflavonoids and correlations with the dynamics of estrogen action in sera following ingestion of a standardized Epimedium extract
Shih Peng Wong et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
William P. Harris et al.
NATURE CLINICAL PRACTICE UROLOGY (2009)
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family
Jianming Xu et al.
NATURE REVIEWS CANCER (2009)
Agent Orange Exposure, Vietnam War Veterans, and the Risk of Prostate Cancer
Karim Chamie et al.
CANCER (2008)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
Scott M. Dehm et al.
CANCER RESEARCH (2008)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells
Xin Huang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Ultrasensitive cell-based bioassay for the measurement of global estrogenic activity of flavonoid mixtures revealing additive, restrictive, and enhanced actions in binary and higher order combinations
Shih Peng et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2007)
Dioxin receptor is a ligand-dependent E3 ubiquitin ligase
Fumiaki Ohtake et al.
NATURE (2007)
Degradation and beyond: Control of androgen receptor activity by the proteasome system
Tomasz Jaworski
CELLULAR & MOLECULAR BIOLOGY LETTERS (2006)
Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP
OW Rokhlin et al.
ONCOGENE (2005)
Androgens activate mitogen-activated protein kinase signaling: Role in neuroprotection
TVV Nguyen et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer
XB Liao et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Androgen receptor (AR) NH2- and COOH-terminal interactions result in the differential influences on the AR-mediated transactivation and cell growth
CL Hsu et al.
MOLECULAR ENDOCRINOLOGY (2005)
Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation
D Morrow et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2004)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions
CJ Loy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase
HK Lin et al.
EMBO JOURNAL (2002)
Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels
L Sheflin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
分享论文
